Covid19
Conditions
Keywords
Solidarity, Hydroxychloroquine, Lopinavir+Ritonavir, Interferon Beta 1a, Remdesivir
Brief summary
This study is an adaptive, randomized, open-label, controlled clinical trial utilizing an adaptive design to compare effects of repurposed drugs with local standard of care alone on major inpatient hospital outcomes. This is performed worldwide in collaboration with WHO.
Interventions
DRUGRemdesivir
Two intravenous loading doses, then daily infusion for 10 days
DRUGHydroxychloroquine
Two oral loading doses, then orally twice daily for 10 days
Orally twice daily for 14 days
DRUGInterferon beta-1a
Daily injection for 6 days
DRUGAcalabrutinib
Orally twice daily for 10 days
Sponsors
University of the Philippines
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Adaptive design
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Consenting adults (age ≥18) hospitalised with the following criteria will be included in the study: 1. Probable or confirmed COVID-19 regardless of severity, i.e., mild, moderate and severe cases 2. Not already receiving any of the study drugs 3. Without known allergy or contraindications to any of the study drugs (in the view of the physician responsible for their care), and 4. Without anticipated transfer within 72 hours to a non-study hospital.
Exclusion criteria
* Patients with contraindications to any of the study drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| All-cause mortality | Number of days from hospital admission up to 28 days post discharge |
Secondary
| Measure | Time frame |
|---|---|
| Duration of hospital stay | Number of days from hospital admission to discharge up to 28 days post admission |
| Time to first receiving ventilation | Number of days from hospital admission to day of receiving ventilatory support up to 28 days post admission |
Countries
Philippines
Outcome results
None listed